@article{SchwarzmeierLeehrBoehnleinetal.2020,
  author    = {Schwarzmeier, Hanna and Leehr, Elisabeth Johanna and B{\"o}hnlein, Joscha and Seeger, Fabian Reinhard and Roesmann, Kati and Gathmann, Bettina and Herrmann, Martin J. and Siminski, Niklas and Jungh{\"o}fer, Markus and Straube, Thomas and Grotegerd, Dominik and Dannlowski, Udo},
  title     = {Theranostic markers for personalized therapy of spider phobia: Methods of a bicentric external cross-validation machine learning approach},
  series = {International Journal of Methods in Psychiatric Research},
  volume    = {29},
  journal   = {International Journal of Methods in Psychiatric Research},
  number    = {2},
  doi       = {10.1002/mpr.1812},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-213430},
  year      = {2020},
  abstract  = {Objectives Embedded in the Collaborative Research Center "Fear, Anxiety, Anxiety Disorders" (CRC-TRR58), this bicentric clinical study aims at identifying biobehavioral markers of treatment (non-)response by applying machine learning methodology with an external cross-validation protocol. We hypothesize that a priori prediction of treatment (non-)response is possible in a second, independent sample based on multimodal markers. Methods One-session virtual reality exposure treatment (VRET) with patients with spider phobia was conducted on two sites. Clinical, neuroimaging, and genetic data were assessed at baseline, post-treatment and after 6 months. The primary and secondary outcomes defining treatment response are as follows: 30\% reduction regarding the individual score in the Spider Phobia Questionnaire and 50\% reduction regarding the individual distance in the behavioral avoidance test. Results N = 204 patients have been included (n = 100 in W{\"u}rzburg, n = 104 in M{\"u}nster). Sample characteristics for both sites are comparable. Discussion This study will offer cross-validated theranostic markers for predicting the individual success of exposure-based therapy. Findings will support clinical decision-making on personalized therapy, bridge the gap between basic and clinical research, and bring stratified therapy into reach. The study is registered at ClinicalTrials.gov (ID: NCT03208400).},
  language  = {en}
}
@phdthesis{Schwarzmeier2023,
  author    = {Schwarzmeier, Hanna},
  title     = {From fear extinction to exposure therapy: neural mechanisms and moderators of extinction},
  doi       = {10.25972/OPUS-22330},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-223304},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Emotional-associative learning processes such as fear conditioning and extinction are highly relevant to not only the development and maintenance of anxiety disorders (ADs), but also to their treatment. Extinction, as the laboratory analogue to behavioral exposure, is assumed a core process underlying the treatment of ADs. Although exposure-based treatments are highly effective for the average patient suffering from an AD, there remains a gap in treatment efficacy with over one third of patients failing to achieve clinically significant symptom relief. There is ergo a pressing need for intensified research regarding the underlying neural mechanisms of aberrant emotional-associative learning processes and the neurobiological moderators of treatment (non-)response in ADs. The current thesis focuses on different applications of the fundamental principles of fear conditioning and extinction by using two example cases of ADs from two different multicenter trials. First, we targeted alterations in fear acquisition, extinction, and its recall as a function of psychopathology in panic disorder (PD) patients compared to healthy subjects using fMRI. Second, exposure-based therapy and pre-treatment patient characteristics exerting a moderating influence on this essential learning process later on (i.e. treatment outcome) were examined using multimodal functional and structural neuroimaging in spider phobia. We observed aberrations in emotional-associative learning processes in PD patients compared to healthy subjects indicated by an accelerated fear acquisition and an attenuated extinction recall. Furthermore, pre-treatment differences related to defensive, regulatory, attentional, and perceptual processes may exert a moderating influence on treatment outcome to behavioral exposure in spider phobia. Although the current results need further replication, on an integrative meta level, results point to a hyperactive defensive network system and deficient emotion regulation processes (including extinction processes) and top-down control in ADs. This speaks in favor of transdiagnostic deficits in important functional domains in ADs. Deficits in transdiagnostic domains such as emotion regulation processes could be targeted by enhancing extinction learning or by means of promising tools like neurofeedback. The detection of pre-treatment clinical response moderators, for instance via machine learning frameworks, may help in supporting clinical decision making on individually tailored treatment approaches or, respectively, to avoid ineffective treatment and its related financial costs. In the long run, the identification of neurobiological markers which are capable of detecting non-responders a priori represents an ultimate goal.},
  subject      = {Extinktion},
  language  = {en}
}